Letermovir
Letermovir (AIC246) is a potent inhibitor of CMV, which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors.
Product Specifications
CAS Number
917389-32-3
Product Name Alternative
AIC246; MK-8228
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
CMV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/letermovir.html
Purity
99.96
Solubility
DMSO : ≥ 100 mg/mL
Smiles
FC1=C(N=C(N2CCN(C3=CC=CC(OC)=C3)CC2)N(C4=CC(C(F)(F)F)=CC=C4OC)[C@H]5CC(O)=O)C5=CC=C1
Molecular Formula
C29H28F4N4O4
Molecular Weight
572.55
Precautions
H302, H312, H332
References & Citations
[1]Marschall M, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56 (2) :1135-7.|[2]Goldner T, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85 (20) :10884-93.|[3]Lischka P, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54 (3) :1290-7.|[4]Wildum S, et al. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59 (6) :3140-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
248894 50 µg
MRPL3 (Mitochondrial Ribosomal Protein L3, MRL3, RPML3)
Sign In for Pricing
View Details 